Loading...
Loading...
In a report published Monday, Sterne Agee analyst Greg T. Bolan reiterated an Underperform rating on
Albany Molecular ResearchAMRI, and raised the price target from $13.00 to $15.00.
In the report, Sterne Agee noted, “Given the official closure of the Oso Pharmaceuticals acquisition on 7/1, we are officially incorporating our estimates for accretion to AMRI's EPS. As shown in this note, even with this accretion, AMRI shares trade at a substantial premium to the peer group. We believe investors have become enamored with AMRI's ‘rollup' strategy and fail to recognize that without taking on more leverage or diluting EPS through an equity offering, the company is limited now in terms of purchasing power.”
Albany Molecular Research closed on Thursday at $21.82.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in